Literature DB >> 31405865

The Siderophore Transporter Sit1 Determines Susceptibility to the Antifungal VL-2397.

Anna-Maria Dietl1, Matthias Misslinger1, Mario M Aguiar1, Vasyl Ivashov2, David Teis2, Joachim Pfister3, Clemens Decristoforo3, Martin Hermann4, Sean M Sullivan5, Larry R Smith5, Hubertus Haas6.   

Abstract

VL-2397 (previously termed ASP2397) is an antifungal, aluminum-chelating cyclic hexapeptide with a structure analogous to that of ferrichrome-type siderophores, whereby replacement of aluminum by iron was shown to decrease the antifungal activity of this compound. Here, we found that inactivation of an importer for ferrichrome-type siderophores, termed Sit1, renders Aspergillus fumigatus resistant to VL-2397. Moreover, expression of the endogenous sit1 gene under the control of a xylose-inducible promoter (to uncouple sit1 expression from iron repression) combined with C-terminal tagging with a fluorescent protein demonstrated localization of Sit1 in the plasma membrane and xylose-dependent VL-2397 susceptibility. This underlines that Sit1-mediated uptake is essential for VL-2397 susceptibility. Under xylose-induced sit1 expression, VL-2397 also retained antifungal activity after replacing aluminum with iron, which demonstrates that VL-2397 bears antifungal activity independent of cellular aluminum importation. Analysis of sit1 expression indicated that the reduced antifungal activity of the iron-chelated VL-2397 is caused by downregulation of sit1 expression by the imported iron. Furthermore, we demonstrate that defects in iron homeostatic mechanisms modulate the activity of VL-2397. In contrast to A. fumigatus and Candida glabrata, Saccharomyces cerevisiae displays intrinsic resistance to VL-2397 antifungal activity. However, expression of sit1 from A. fumigatus, or its homologue from C. glabrata, resulted in susceptibility to VL-2397, which suggests that the intrinsic resistance of S. cerevisiae is based on lack of uptake and that A. fumigatus, C. glabrata, and S. cerevisiae share an intracellular target for VL-2397.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Aspergillus fumigatuszzm321990; Saccharomyces cerevisiaezzm321990; Sit1; antifungal drug; iron; siderophores

Mesh:

Substances:

Year:  2019        PMID: 31405865      PMCID: PMC6761561          DOI: 10.1128/AAC.00807-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  45 in total

1.  The genetics of Aspergillus nidulans.

Authors:  G PONTECORVO; J A ROPER; L M HEMMONS; K D MACDONALD; A W J BUFTON
Journal:  Adv Genet       Date:  1953       Impact factor: 1.944

2.  Transformation of Aspergillus based on the hygromycin B resistance marker from Escherichia coli.

Authors:  P J Punt; R P Oliver; M A Dingemanse; P H Pouwels; C A van den Hondel
Journal:  Gene       Date:  1987       Impact factor: 3.688

3.  Gene targeting in Aspergillus fumigatus by homologous recombination is facilitated in a nonhomologous end- joining-deficient genetic background.

Authors:  Sven Krappmann; Christoph Sasse; Gerhard H Braus
Journal:  Eukaryot Cell       Date:  2006-01

4.  Antifungal susceptibility testing in Aspergillus spp. according to EUCAST methodology.

Authors:  C Lass-Flörl; M Cuenca-Estrella; D W Denning; J L Rodriguez-Tudela
Journal:  Med Mycol       Date:  2006-09-01       Impact factor: 4.076

Review 5.  The Iron age of host-microbe interactions.

Authors:  Miguel P Soares; Günter Weiss
Journal:  EMBO Rep       Date:  2015-10-16       Impact factor: 8.807

6.  SidL, an Aspergillus fumigatus transacetylase involved in biosynthesis of the siderophores ferricrocin and hydroxyferricrocin.

Authors:  Michael Blatzer; Markus Schrettl; Bettina Sarg; Herbert H Lindner; Kristian Pfaller; Hubertus Haas
Journal:  Appl Environ Microbiol       Date:  2011-05-27       Impact factor: 4.792

7.  Structural requirements for the activity of the MirB ferrisiderophore transporter of Aspergillus fumigatus.

Authors:  Isabelle Raymond-Bouchard; Cassandra S Carroll; Jason R Nesbitt; Kevin A Henry; Linda J Pinto; Mina Moinzadeh; Jamie K Scott; Margo M Moore
Journal:  Eukaryot Cell       Date:  2012-08-17

8.  HapX-mediated adaption to iron starvation is crucial for virulence of Aspergillus fumigatus.

Authors:  Markus Schrettl; Nicola Beckmann; John Varga; Thorsten Heinekamp; Ilse D Jacobsen; Christoph Jöchl; Tarek A Moussa; Shaohua Wang; Fabio Gsaller; Michael Blatzer; Ernst R Werner; William C Niermann; Axel A Brakhage; Hubertus Haas
Journal:  PLoS Pathog       Date:  2010-09-30       Impact factor: 6.823

9.  Ferricrocin, a siderophore involved in intra- and transcellular iron distribution in Aspergillus fumigatus.

Authors:  Anja Wallner; Michael Blatzer; Markus Schrettl; Bettina Sarg; Herbert Lindner; Hubertus Haas
Journal:  Appl Environ Microbiol       Date:  2009-04-17       Impact factor: 4.792

10.  Enhanced labile plasma iron in hematopoietic stem cell transplanted patients promotes Aspergillus outgrowth.

Authors:  Verena Petzer; Martin Wermke; Piotr Tymoszuk; Dominik Wolf; Markus Seifert; Rıdvan Ovaçin; Sylvia Berger; Dorothea Orth-Höller; Lorin Loacker; Günter Weiss; Hubertus Haas; Uwe Platzbecker; Igor Theurl
Journal:  Blood Adv       Date:  2019-06-11
View more
  11 in total

1.  First-in-Human Phase 1 Study To Assess Safety, Tolerability, and Pharmacokinetics of a Novel Antifungal Drug, VL-2397, in Healthy Adults.

Authors:  Mammen P Mammen; Danielle Armas; Frank H Hughes; Andrew M Hopkins; Cindy L Fisher; Pamela A Resch; Denis Rusalov; Sean M Sullivan; Larry R Smith
Journal:  Antimicrob Agents Chemother       Date:  2019-10-22       Impact factor: 5.191

Review 2.  The Future of Antifungal Drug Therapy: Novel Compounds and Targets.

Authors:  Caroline Mota Fernandes; Deveney Dasilva; Krupanandan Haranahalli; J Brian McCarthy; John Mallamo; Iwao Ojima; Maurizio Del Poeta
Journal:  Antimicrob Agents Chemother       Date:  2021-01-20       Impact factor: 5.191

3.  Invasive candidiasis: investigational drugs in the clinical development pipeline and mechanisms of action.

Authors:  Martin Hoenigl; Rosanne Sprute; Amir Arastehfar; John R Perfect; Cornelia Lass-Flörl; Romuald Bellmann; Juergen Prattes; George R Thompson; Nathan P Wiederhold; Mohanad M Al Obaidi; Birgit Willinger; Maiken C Arendrup; Philipp Koehler; Matteo Oliverio; Matthias Egger; Ilan S Schwartz; Oliver A Cornely; Peter G Pappas; Robert Krause
Journal:  Expert Opin Investig Drugs       Date:  2022-06-15       Impact factor: 6.498

Review 4.  Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy.

Authors:  Gina Wall; Jose L Lopez-Ribot
Journal:  Antibiotics (Basel)       Date:  2020-07-25

Review 5.  Carrier-Mediated Drug Uptake in Fungal Pathogens.

Authors:  Mónica Galocha; Inês Vieira Costa; Miguel Cacho Teixeira
Journal:  Genes (Basel)       Date:  2020-11-09       Impact factor: 4.096

6.  Cyclopeptide Derivatives from the Sponge-Derived Fungus Acremonium persicinum F10.

Authors:  Yingxin Li; Zhiyong Li
Journal:  Mar Drugs       Date:  2021-09-24       Impact factor: 5.118

Review 7.  Pharmacodynamics, Mechanisms of Action and Resistance, and Spectrum of Activity of New Antifungal Agents.

Authors:  Nathan P Wiederhold
Journal:  J Fungi (Basel)       Date:  2022-08-16

Review 8.  Activity and Mechanism of Action of Antifungal Peptides from Microorganisms: A Review.

Authors:  Tianxi Li; Lulu Li; Fangyuan Du; Lei Sun; Jichao Shi; Miao Long; Zeliang Chen
Journal:  Molecules       Date:  2021-06-05       Impact factor: 4.411

Review 9.  Antimicrobial Peptides: a New Frontier in Antifungal Therapy.

Authors:  Giuseppe Buda De Cesare; Shane A Cristy; Danielle A Garsin; Michael C Lorenz
Journal:  mBio       Date:  2020-11-03       Impact factor: 7.867

Review 10.  Advances in anti-fungal therapies.

Authors:  Grant Waterer
Journal:  Mycopathologia       Date:  2021-07-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.